{
  "query": "MPLT",
  "resolved": {
    "ticker": "MPLT",
    "cik": "0001770069",
    "title": "MapLight Therapeutics, Inc."
  },
  "signals": [
    {
      "type": "trial_to_filing",
      "headline": "MapLight Therapeutics, Inc. (MPLT) — PHASE2 protocol updated 7 days ago",
      "entity": "MapLight Therapeutics",
      "ticker": "MPLT",
      "cik": "0001770069",
      "tickerConfidence": 0.95,
      "upstream": {
        "event": "Clinical trial status (PHASE2)",
        "detail": "An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis",
        "nctId": "NCT07459660",
        "date": "2029-03"
      },
      "observed": {
        "event": "protocol updated 7 days ago",
        "nctId": "NCT07459660"
      },
      "predicted": {
        "event": "SEC 8-K / press release on Phase 3 initiation",
        "leadTime": "18-36 mo",
        "baseRate": 0.29,
        "note": "Reg FD requires prompt disclosure of material clinical results."
      },
      "leadTime": "Phase-transition base rate 28% (Wong/Siah/Lo 2019)",
      "confidence": 0.35,
      "links": {
        "trial": "https://clinicaltrials.gov/study/NCT07459660",
        "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001770069&type=8-K"
      }
    },
    {
      "type": "trial_to_filing",
      "headline": "MapLight Therapeutics, Inc. (MPLT) — PHASE2 protocol updated 7 days ago",
      "entity": "MapLight Therapeutics",
      "ticker": "MPLT",
      "cik": "0001770069",
      "tickerConfidence": 0.95,
      "upstream": {
        "event": "Clinical trial status (PHASE2)",
        "detail": "A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis",
        "nctId": "NCT06887192",
        "date": "2027-12"
      },
      "observed": {
        "event": "protocol updated 7 days ago",
        "nctId": "NCT06887192"
      },
      "predicted": {
        "event": "SEC 8-K / press release on Phase 3 initiation",
        "leadTime": "18-36 mo",
        "baseRate": 0.29,
        "note": "Reg FD requires prompt disclosure of material clinical results."
      },
      "leadTime": "Phase-transition base rate 28% (Wong/Siah/Lo 2019)",
      "confidence": 0.35,
      "links": {
        "trial": "https://clinicaltrials.gov/study/NCT06887192",
        "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001770069&type=8-K"
      }
    }
  ],
  "recentFilings": {
    "name": "MapLight Therapeutics, Inc.",
    "sicDescription": "Pharmaceutical Preparations",
    "filings": [
      {
        "form": "8-K",
        "date": "2026-07-27",
        "accession": "0001193125-26-316820",
        "items": "7.01,8.01,9.01"
      },
      {
        "form": "8-K",
        "date": "2026-06-24",
        "accession": "0001193125-26-280243",
        "items": "5.07"
      },
      {
        "form": "8-K",
        "date": "2026-06-22",
        "accession": "0001193125-26-276691",
        "items": "7.01,8.01,9.01"
      },
      {
        "form": "8-K",
        "date": "2026-06-18",
        "accession": "0001193125-26-276065",
        "items": "5.02"
      },
      {
        "form": "8-K",
        "date": "2026-05-14",
        "accession": "0001193125-26-224067",
        "items": "2.02,7.01,9.01"
      }
    ]
  },
  "disclaimer": "Research/informational. NOT investment advice.",
  "generatedAt": "2026-08-05T09:00:27.014Z"
}